{"id":129701,"date":"2026-07-15T06:53:28","date_gmt":"2026-07-15T06:53:28","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/129701\/"},"modified":"2026-07-15T06:53:28","modified_gmt":"2026-07-15T06:53:28","slug":"novo-nordisk-cpsenovo-b-could-be-13-overvalued-following-its-vivani-deal","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/129701\/","title":{"rendered":"Novo Nordisk (CPSE:NOVO B) Could Be 13% Overvalued Following Its Vivani Deal"},"content":{"rendered":"\n

Never miss an important update on your stock portfolio<\/a> and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. <\/p>\n

Vivani Medical’s new agreement gives Novo Nordisk (CPSE:NOVO B) access to evaluate NPM-139, a semaglutide implant for chronic weight management, offering investors another data point on the company’s obesity drug delivery options. <\/p>\n

See our latest analysis for Novo Nordisk.<\/a> <\/p>\n

The Vivani agreement lands at a time when Novo Nordisk’s DKK323.15 share price has shown strong short term momentum, with a 30 day share price return of 18.81% and a 90 day share price return of 35.72%. Over longer periods, the 1 year total shareholder return is down 23.68% and the 3 year total shareholder return is down 32.45%. This points to a stock where sentiment has improved recently, while long term holders are still under water. <\/p>\n

If Novo Nordisk’s obesity pipeline has your attention, it can be useful to see what else is gaining traction in related areas by checking out 129 healthcare AI stocks<\/a> <\/p>\n

After a sharp rebound in Novo Nordisk’s share price, yet a still weak longer term track record, the key issue now is whether the current valuation leaves enough upside to justify the risks you are taking. <\/p>\n

Most Popular Narrative: 12.6% Overvalued <\/p>\n

Novo Nordisk’s last close of DKK323.15 sits above the narrative fair value of DKK287, so according to ctmlin910 the current price already bakes in rich expectations. <\/p>\n

The US obesity population suggests a theoretical GLP-1 market exceeding $80 billion annually by 2035. However, realised revenue depends on access. Manufacturing capacity is constrained until roughly 2029, limiting volume growth regardless of demand. Reimbursement remains uneven. Medicare does not broadly cover obesity medications, and commercial payors impose strict prior authorisation due to budget impact. While the SELECT cardiovascular outcomes data strengthens the health economic argument, it has not yet triggered universal coverage expansion. <\/p>\n

Read the complete narrative.<\/a> <\/p>\n

Want to understand why this narrative still lands above today’s price? It leans heavily on obesity revenue scale, access assumptions, and a tight future earnings multiple. The interplay between volume limits and pricing power is key. The details in the projections explain how DKK287 is reached. <\/p>\n

Result: Fair Value of DKK287 (OVERVALUED) <\/p>\n

Have a read of the narrative in full and understand what’s behind the forecasts.<\/a> <\/p>\n

However, if Novo Nordisk expands manufacturing capacity faster than expected or reimbursement broadens meaningfully, the current “overvalued” narrative could prove too conservative. <\/p>\n

Find out about the key risks to this Novo Nordisk narrative.<\/a> <\/p>\n

Another View: What Novo Nordisk’s P\/E Is Saying <\/p>\n

The narrative fair value of DKK287 suggests Novo Nordisk is 12.6% overvalued at DKK323.15, but the P\/E picture is very different. On 11.7x earnings, the stock trades well below peers at 25.8x and a fair ratio of 22.9x, which points to a sizable valuation gap that could either close or persist. Which story do you put more weight on? <\/p>\n

To see how this earnings based view compares with other signals, including peers and that fair ratio the market could move toward, See what the numbers say about this price \u2014 find out in our valuation breakdown.<\/a> <\/p>\n

\"CPSE:NOVO<\/a> CPSE:NOVO B P\/E Ratio as at Jul 2026 Next Steps <\/p>\n

If this mix of confidence and caution around Novo Nordisk leaves you unsure, it is worth moving fast and testing the numbers for yourself. A straightforward place to start is by weighing the 3 key rewards and 4 important warning signs. <\/p>\n

Looking for more investment ideas beyond Novo Nordisk? <\/p>\n

If Novo Nordisk has sharpened your focus on quality opportunities, do not stop here. Fresh stock ideas can help you build a stronger, more resilient portfolio. <\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. <\/p>\n

Companies discussed in this article include NOVO-B.CO<\/a>. <\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors…\n","protected":false},"author":2,"featured_media":129702,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[272,948,1739],"class_list":["post-129701","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-novo-nordisk","tag-share-price","tag-total-shareholder-return"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116922679483611574","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/129701","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=129701"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/129701\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/129702"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=129701"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=129701"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=129701"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}